Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹23,217 Cr
Revenue (TTM)
₹172 Cr
Net Profit (TTM)
₹-366 Cr
ROE
-62.7 %
ROCE
-21.4 %
P/E Ratio
--
P/B Ratio
3.9
Industry P/E
39.7
EV/EBITDA
48.9
Div. Yield
0 %
Debt to Equity
1.4
Book Value
₹96.7
EPS
₹-97.5
Face value
1
Shares outstanding
114,466,021
CFO
₹--
EBITDA
₹--
Net Profit
₹--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Onesource Specialty Pharma
| -- | 24.6 | 27.1 | -- | -- | -- | -- |
|
BSE Healthcare
| -4.6 | 0.9 | 5.1 | 17.0 | 27.1 | 21.6 | 10.3 |
|
BSE Mid Cap
| -2.0 | 0.8 | 10.6 | -0.8 | 28.8 | 28.9 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Onesource Specialty Pharma
|
2,029.7 | 23,217.1 | 171.9 | -365.7 | -- | -62.7 | -- | 3.9 |
| 934.7 | 18,489.7 | 6,672.1 | 582.0 | 10.9 | 11.6 | 31.7 | 3.6 | |
| 983.0 | 37,721.1 | 1,197.6 | 264.8 | 24.9 | 14.6 | 140.8 | 22.1 | |
| 1,636.7 | 46,194.9 | 13,321.7 | 1,047.1 | 14.0 | 14.6 | 44.1 | 5.2 | |
| 1,107.9 | 17,657.9 | 7,234.5 | 836.8 | 11.1 | 7.9 | 21 | 2.8 | |
| 651.0 | 35,141.7 | 5,554.0 | 354.4 | 11.3 | 8.3 | 98.1 | 7.9 | |
| 875.1 | 15,677.5 | 4,429.5 | 1,883.4 | 44.3 | 25.6 | 8.3 | 2.1 | |
| 195.1 | 25,927.0 | 9,151.2 | 18.2 | 6.9 | 1.1 | 284.5 | 3.2 | |
| 631.2 | 25,463.8 | 3,642.4 | 496.2 | 16.6 | 10.4 | 51.3 | 5.4 | |
| 1,730.8 | 28,120.6 | 3,012.0 | -57.0 | 5.8 | -1.2 | -- | 6.5 |
No Review & Analysis are available.
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India and internationally. The company provides... end-to-end CDMO services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. OneSource Specialty Pharma Limited was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. The company was incorporated in 2007 and is based in Bengaluru, India. Read more
Incorporated
2007
Chairman
--
Managing Director
Neeraj Sharma
Headquarters
Navi Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Onesource Specialty Pharma Ltd stood at ₹ 1,309 Cr as on 31-Mar-24
The share price of Onesource Specialty Pharma Ltd is ₹2,029.70 (NSE) and ₹2,028.30 (BSE) as of 20-Jun-2025 IST. Onesource Specialty Pharma Ltd has given a return of --% in the last 1 years.
Onesource Specialty Pharma Ltd has a market capitalisation of ₹ 23,217 Cr as on 20-Jun-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Onesource Specialty Pharma Ltd is 3.95 times as on 20-Jun-2025, a 6% premium to its peers’ median range of 3.72 times.
Since, TTM earnings of Onesource Specialty Pharma Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Onesource Specialty Pharma Ltd and enter the required number of quantities and click on buy to purchase the shares of Onesource Specialty Pharma Ltd.
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India and internationally. The company provides end-to-end CDMO services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. OneSource Specialty Pharma Limited was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. The company was incorporated in 2007 and is based in Bengaluru, India.
The prominent promoters of Onesource Specialty Pharma Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
TENSHI PHARMACEUTICALS PRIVATE LIMITED |
17.94%
|
|
KARUNA BUSINESS SOLUTIONS LLP |
6.89%
|
|
PRONOMZ VENTURES LLP |
6.8%
|
The chairman of the company is , and the managing director is Neeraj Sharma.
The promoters of Onesource Specialty Pharma Ltd have pledged 6.87% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
46,195
|
|
|
37,721
|
|
|
35,142
|
|
|
28,121
|
|
|
25,927
|
|
|
25,464
|
|
|
18,490
|
|
|
17,658
|
|
|
15,677
|
| Onesource Specialty Pharma Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-62.66
|
|
Operating margin(%)
|
-95.7
|
|
Net Margin(%)
|
-207.61
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Onesource Specialty Pharma Ltd was ₹-366 Cr.
₹-81.60
(
